Targeting the HER family with pan-HER effectively overcomes resistance to cetuximab

Molecular Cancer Therapeutics

Volumn 15, Issue 9, 2016, Pages 2175-2186

  Iida, Mari ^a   Bahrar, Harsh ^a,b   Brand, Toni M ^a   Pearson, Hannah E ^a   Coan, John P ^a   Orbuch, Rachel A ^a   Flanigan, Bailey G ^a   Swick, Adam D ^a   Prabakaran, Prashanth J ^a   Lantto, Johan ^c   Horak, Ivan D ^c   Kragh, Michael ^c   Salgia, Ravi ^d   Kimple, Randy J ^a   Wheeler, Deric L ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Symphogen AS   (Denmark)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HEAD AND NECK TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990963161     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0012     Document Type: Article

References (51)

1. Yarden Y, Pines G. The ERBB network: at last, cancer therapymeets systems biology. Nat Rev Cancer 2012;12:553-63.
2. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303.
3. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
4. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004;58:959-65.
5. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-15.
6. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factorinduced epidermal growth factor receptor transactivation. Mol Cell Biol 2001;21:6387-94.
7. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34-74.
8. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177-84.
9. Douillard JY, Pirker R, O'Byrne KJ, Kerr KM, Storkel S, Von Heydebreck A, et al. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J Thorac Oncol 2014;9:717-24.
10. Pirker R. EGFR-directed monoclonal antibodies in non-small cell lung cancer. Target Oncol 2013;8:47-53.
11. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 2011;11:777-92.
12. Vlacich G, Coffey RJ. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell 2011;20:423-5.
13. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944-56.
14. Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, et al. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer 2014;13:242.
15. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-inducedHER reprogramming in "resistant" breast carcinoma cells. Cancer Res 2009;69:2191-4.
16. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
17. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013;13:663-73.
18. Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. mAbs 2011;3:338-51.
19. Jacobsen HJ, Poulsen TT, Dahlman A, Kjaer I, Koefoed K, Sen JW, et al. Pan-HER, an antibody mixture simultaneously targeting EGFR, HER2, and HER3, effectively overcomes tumor heterogeneity and plasticity. Clin Cancer Res 2015;21:4110-22.
20. Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, et al. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 2013;15:1196-206.
21. Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, et al. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther 2011;12:436-46.
22. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 2011;30:561-74.
23. Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 2013;19:855-64.
24. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, et al. AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res 2015;21:2601-12.
25. Stein AP, Saha S, Liu CZ, Hartig GK, Lambert PF, Kimple RJ. Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts. PLoS One 2014;9:e100995.
26. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
27. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
28. Pirker R, Pereira JR, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
29. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
30. Khelwatty SA, Essapen S, Bagwan I, Green M, Seddon AM, Modjtahedi H. Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PLoS One 2014;9:e91139.
31. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-7.
32. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014;4:1269-80.
33. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009;8:696-703.
34. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70:588-97.
35. Huang S, Peet CR, Saker J, Li C, Armstrong EA, Kragh M, et al. Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers. Mol Cancer Ther 2013;12:2772-81.
36. Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, et al. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A 2013;110:1815-20.
37. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005;11:6390-9.
38. Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst JL, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther 2014;13:1345-55.
39. Zheng L, Tan W, Zhang J, Yuan D, Yang J, Liu H. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother 2014;63:581-6.
40. Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, et al. Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Sci Signal 2015;8: ra53.
41. Francis DM, Huang S, Armstrong EA, Werner LR, Hullett CR, Li C, et al. Pan-HER receptor inhibition augments radiation response in human lung and head and neck cancer models. Clin Cancer Res 2016;22:633-43.
42. Nielsen CH, Jensen MM, Kristensen LK, Dahlman A, Frohlich C, Jacobsen HJ, et al. In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography. Oncotarget 2015;6:37486-99.
43. Hu S, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 2015;75:159-70.
44. Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res 2013;19:610-9.
45. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 2010;5:e12702.
46. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, et al. AXL mediates resistance to cetuximab therapy. Cancer Res 2014;74:5152-64.
47. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526:263-7.
48. Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, et al. Afatinib against esophageal or head-and-neck cell squamous carcinoma: significance of activating oncogenic HER4 mutations in HNSCC. Mol Cancer Ther. 2016 May 20.[Epub ahead of print].
49. Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 2014;39:465-74.
50. Bertotti A, Sassi F. Molecular pathways: sensitivity and resistance to anti-EGFR antibodies. Clin Cancer Res 2015;21:3377-83.
51. Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, et al. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol 2014;9:775-83.